Full-Time

Senior Scientist

Applied Machine Learning and Generative AI, Pharma R&D

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Senior

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Category
Applied Machine Learning
AI & Machine Learning
Required Skills
Python
Data Science
R
SQL
Machine Learning
Data Analysis
Requirements
  • PhD and additional 2+ years of working experience or Masters and additional 4+ years of working experience
  • Quantitative and computational skills (e.g. Applied Machine Learning, Generative AI, Computational Biology, Biostatistics/Statistical Genetics, and/or Bioinformatics)
  • Biological or medical knowledge (e.g. oncology, immunology, genomics, transcriptomics)
  • Target, drug or diagnostic discovery, or clinical drug development
  • Proficient in R, Python, and SQL, and respective packages for computational biology and machine learning
  • Applicable knowledge of machine learning and statistical modeling
  • Strong understanding of the uses of artificial intelligence in molecular data analysis or drug discovery/development
  • Experience in integrative modeling of multi-modal clinical and omics data
  • Excellent written and verbal communication skills, with the ability to present complex information clearly and persuasively to diverse audiences
  • Comfort in a client-facing role
  • Motivated and thrive in a fast-paced environment, willing to shift priorities seamlessly
Responsibilities
  • Become an expert in Tempus’ vast epidemiological, clinical, ‘omic and imaging data, along with the latest tools and techniques for their analysis and modeling
  • Drive continual improvement of the Tempus platform for pharmaceutical R&D by integrating client feedback, staying ahead of research and industry trends, and championing new opportunities
  • Work with Research, Engineering & Data Science teams across Tempus’ expansive data science community to develop and deliver innovative computational solutions
  • Gain proficiency in pharmaceutical companies' strategies, drug modalities, and pipelines to identify where the Tempus platform can add value
  • Co-develop solutions with client science and clinical teams, and design, develop, and execute complex translational research projects leveraging the Tempus platform to advance their drug R&D programs
  • Skillfully navigate client interactions to extract and communicate the most impactful insights driving new R&D opportunities; effectively communicate complex technical results and methodologies to diverse external stakeholders
  • Continuously immerse yourself in the latest industry trends, best practices, and advancements in machine learning and AI to revolutionize drug R&D
Desired Qualifications
  • Strong peer-reviewed publication record
  • Strong understanding of cancer biology
  • Expertise in one or more of the following: in vitro data analysis and phenomics, network and systems biology, mechanistic modeling and simulation, knowledge analytics, deconvolution and causal inference, integrative analysis of multi-modal data, real-world evidence, and survival analysis
  • Previous experience working with large transcriptome and NGS data sets
  • Experience with R package development
  • Goal orientation, self-motivation, and drive to make a positive impact in healthcare

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, distinguishing itself through its focus on personalized medicine and extensive cancer research.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus secured $560 million in debt financing to support growth and acquisitions.
  • Partnerships with Stemline and Artera expand Tempus' AI platform applications.
  • The launch of the Olivia app empowers patients with AI-driven health management.

What critics are saying

  • High debt levels may strain Tempus' financial stability if revenue targets aren't met.
  • Increased competition from AI healthcare platforms could erode Tempus' market share.
  • Regulatory challenges in AI and data privacy could impact Tempus' operations.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus' AI-driven liquid biopsy assay enhances cancer detection and profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.